Among patients with severe mitral regurgitation (MR) who are poor candidates for surgery but survive a complex percutaneous procedure and its aftermath, mitral valve replacement (TMVR) with the Tendyne (Abbott) transcatheter device may reduce the severity of disease, improve symptoms, and lower the rate of hospitalization for heart failure over 2 years, according to new data.
Yet two in five people treated died during follow-up, most within the first 3 months, leading some to insist that patient selection needs to be further refined before this procedure can be used more routinely.
Progress in the space of transcatheter mitral valve treatment has been slow going compared with advancements in aortic valve disease. Three years ago, the COAPT trial made waves showing the success of transcatheter edge-to-edge mitral valve repair using the MitraClip (Abbott) in patients with heart failure and severe functional MR, but not all anatomies are suited to this procedure. Prior to that, 1-year findings from the Tendyne Global Feasibility Study were published for the first 30 patients implanted with the device, a trileaflet porcine pericardial valve that is delivered transapically and permanently anchored to the apex with a tether. Encouraging 30-day data in the first 100 patients came in 2018, and the device was granted CE Mark approval in early 2020.
For the transcatheter mitral valves, it has been difficult to identify the right population of patients to treat, and it's also a much more difficult valve to work with, lead author David Muller, MBBS, MD (St Vincents Hospital, Sydney, Australia), told TCTMD. There have been a number of devices that haven't made the grade, if you will, and have been discontinued. Tendyne is the only valve that has actually done well in the commercial sense. There are now more than 800 patients who have been treated with this device.
The 2-year findings of the same first 100 patients (mean age 74.7 years; 69% male) are now published in the November 9, 2021, issue of the Journal of the American College of Cardiology and confirm what was observed at 1 year. Heart failure hospitalization was less frequent than it had been preprocedure (0.51 vs 1.30 events per year; P < 0.0001), 93.2% of surviving patients had no MR at 2 years, and none had > 1+ MR. The 2-year rate of all-cause mortality remained high at 39.0%, with 43.6% of deaths occurring in the first 90 days.
For survivors, the device appeared to improve symptoms: 88.5% of patients were in NYHA functional class I or II at 1 year, a proportion that dipped only slightly, to 81.6%, at 2 years. From baseline to 2 years, reductions in both LVEF (45.6% to 39.8%; P = 0.0012) and estimated right ventricular systolic pressure (mean 47.6 to 32.5 mm Hg; P < 0.005) were seen among survivors.
MVARC-defined major, extensive, or life-threatening, or fatal bleeding was observed in about one-fourth of the population, but only four of the 27 total events were procedural/device related, none of which were fatal. Valve thrombosis was identified in six patients all before 6 months when oral anticoagulation was not yet mandatory.
It's clear that this procedure does carry some risk in the initial postoperative period, but for patients who survive that period, and particularly those who are still doing well at 1 year, the outcomes beyond that are excellent, Muller said. So we're really very pleased about that.
Patient Selection Is Key
Commenting on the study for TCTMD, Firas Zahr, MD (Oregon Health and Science University, Portland), said he was reassured to finally see intermediate-term data that renew trust in the therapy. The field of TMVRwith a big R [for replacement]has been a little bit challenged by our ability to identify the right patient population for this therapy, he said. The 90-day mortality rate tells us that despite a highly selective group of patients who pass screen fail, we still need a lot of work to do to understand which patient population will benefit the most from this therapy. However, it seems like [for] the patients who are surviving at 2 years, their functional class, their heart failure hospitalization, their quality of life is much better.
In an accompanying editorial, Josep Rods-Cabau, MD, PhD (Quebec Heart & Lung Institute, Quebec City, Canada), and colleagues focus on the need for better patient selection, what they deem an unsolved issue in the field. Echoing Zahrs comments, they note that the screening failure rate in TMVR trials has ranged from 40%-70%. So, it is concerning that despite these highly selective criteria, the risk of treatment futility within the months following the procedure seems to be high, likely due to the high comorbidity burden of current TMVR candidates, they stress.
Muller said that most of the patients who seem optimal for TMVR with Tendyne will be elderly, with poor heart function and plenty of comorbidities. But if we take those who are too elderly and too frail, then we may fix their valve, but they'll die from other causes and from poor heart function, he said. The same was seen in early TAVI studies, he noted, where limiting procedures to the sickest patients inevitably led to worse outcomes. Over the next few years, he predicted, the field will increasingly turn to a population of patients perhaps who are younger and who are not as frail, who can survive the initial surgery.
The upcoming SUMMIT trial will include patients who are eligible for both MitraClip and TMVR and will give a better sense I think of whether this can compete with MitraClip or whether those who are anatomically eligible for MitraClip should have that and only the patients who just are not suitable for that will be considered then for this procedure, Muller continued.
The editorialists also call out the negative impact of the transapical access in a frail population with left ventricular dysfunction. Switching from a transapical to a transseptal approach might reduce recovery time and morbidity as well as access-related myocardial injury, they say. Unfortunately, due to the current design of the Tendyne valve, the ability to switch from transapical to transseptal implantation with this platform is highly unlikely.
This is probably true, Muller confirms. There's been a lot of work from a lot of companies trying to develop a similar concept that can be deployed as a transeptal procedure, . . . but I would have to say that no company has really got that one sorted yet, he said, adding that with the Tendyne valve specifically, the importance of the tethers effect on outcomes remains unknown. From an engineering point of view, it can be very hard to create a device that is tethered to the apex from a transeptal approach.
Rods-Cabau and colleagues also discuss the balance of bleeding and valve thrombotic risk among patients who undergo TMVR as one of the main challenges of the procedure. Of note, there were no cases of valve thrombosis during the second postoperative year, suggesting that relatively short periods of aggressive antithrombotic therapy may be the strategy with the best risk/benefit ratio in these patients, they write. Further studies are urgently needed to determine the optimal type and duration of antithrombotic therapy in this field.
In a JACC podcast summarizing the study, Editor-in-Chief Valentin Fuster MD, PhD (Icahn School of Medicine at Mount Sinai, New York, NY), said while the study has good news, intermediate news, and bad news, the evidence is not convincing enough yet to see a definite clinical use of this procedure given available medicines. In my view, right or wrong, my approach would be just trying to improve symptoms, especially given the difficulty of life following any potential procedure-related complications he said.
Read the original:
Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR - TCTMD
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]